Jane Street Group LLC Purchases Shares of 177,260 Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Jane Street Group LLC acquired a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 177,260 shares of the company’s stock, valued at approximately $2,834,000. Jane Street Group LLC owned 0.16% of Centessa Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after buying an additional 826 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after acquiring an additional 1,509 shares during the period. Quarry LP grew its position in shares of Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares during the last quarter. Sandia Investment Management LP acquired a new position in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $90,000. Finally, Fred Alger Management LLC acquired a new stake in Centessa Pharmaceuticals during the 2nd quarter worth approximately $99,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 87,496 shares of the company’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $18.46, for a total transaction of $1,615,176.16. Following the completion of the transaction, the chief executive officer now directly owns 575,661 shares in the company, valued at approximately $10,626,702.06. This represents a 13.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Karen M. Anderson sold 10,624 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $17.32, for a total value of $184,007.68. Following the completion of the transaction, the insider now owns 71,525 shares of the company’s stock, valued at $1,238,813. The trade was a 12.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 374,642 shares of company stock valued at $6,425,926. 11.59% of the stock is currently owned by insiders.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock opened at $17.16 on Friday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.26 billion, a PE ratio of -11.22 and a beta of 1.52. The company has a 50 day moving average of $16.64 and a 200-day moving average of $13.57. Centessa Pharmaceuticals plc has a 1-year low of $6.65 and a 1-year high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. As a group, equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Guggenheim upped their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. BMO Capital Markets raised their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $11.00 to $26.00 in a report on Thursday, September 19th. B. Riley began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 target price on the stock. Finally, Jefferies Financial Group boosted their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.